However, treatment of t(16;21) AML with all-trans retinoic acid (ATRA) has recently been shown to recruit ERG to new genome-wide binding sites, suggesting that the RARa/RXR heterodimer is capable of reprogramming ERG binding. This evidence concerns the gene RARA and acute myeloid leukemia.